Research programme: antibacterials - Achillion/FOB Synthesis

Drug Profile

Research programme: antibacterials - Achillion/FOB Synthesis

Alternative Names: FSI-1297; FSI-1671; FSI-1686

Latest Information Update: 25 Jun 2013

Price : $50

At a glance

  • Originator FOB Synthesis
  • Developer Achillion Pharmaceuticals; FOB Synthesis
  • Class Carbapenems
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 25 Jun 2013 Preclinical development is ongoing in USA
  • 03 Oct 2011 Preclinical trials in Bacterial infections in USA (Parenteral)
  • 19 Sep 2011 Preclinical antimicrobial data presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2011) ,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top